

Influenza Session

Emmanuel (Chip) Walter, MD, MPH
Chair, Influenza Work Group

Advisory Committee on Immunization Practices
February 27, 2019

Influenza Work Group

ACIP Members

Emmanuel (Chip) Walter (Chair)

Robert Atmar

Kevin Ault

Hank Bernstein

Peter Szilagyi

***Ex Officio* Members**

Michael Cooper (NIH)

Cynthia Nolletti (FDA)

Roshan Ramanathan (FDA)

Chris Roberts (NIH)

Susan Wollersheim (FDA)

Consultants

Ed Belongia

Jeff Duchin

Wendy Keitel

Jamie Loehr

Kathy Neuzil

Liaison Representatives

Sarah Coles (AAFP)

Buddy Creech (PIDS)

Sarah Despres (Consumer Representative)

Sandra Fryhofer (ACP; AMA)

Ian Gemmill (NACI)

Denise Jamieson (ACOG)

Marie-Michèle Léger (AAPA)

Susan Lett (CSTE)

Flor Munoz (AAP)

William Schaffner (NFID)

Rob Schechter (AIM)

Ken Schmader (AGS)

Patsy Stinchfield (NAPNAP)

Tamara Sheffield (AHIP)

Matthew Zahn (NACCHO)

Recap of Influenza Session, October 2018

- Presentation of the PREVENT study of effectiveness of influenza vaccine in preventing hospitalization among pregnant women
- Presentation of study of Fluzone Quadrivalent (Sanofi Pasteur) at a 0.5mL dose for children aged 6 through 35 months
 - Approved by FDA in January 2019

Work Group Discussions Since October 2018

- 2018-19 season U.S. influenza activity
- Interim 2018-19 season vaccine effectiveness estimates (U.S. Flu VE Network)
- Results of the 3rd Vaccine Safety Datalink study of inactivated influenza vaccines (IIVs) and spontaneous abortion (SAB) among pregnant women
 - Follow-up to an earlier study presented to ACIP in October 2017, which detected an association between receipt of IIV and SAB in first 28 days post vaccination when an H1N1pdm09-containing vaccine had also been received the previous season.

Agenda Overview

- **2018-19 U.S. Surveillance Update**
 - Ms. Lynnette Brammer, CDC/NCIRD
- **Interim Estimates of 2018–19 Seasonal Influenza Vaccine Effectiveness--US Flu VE Network**
 - Dr. Brendan Flannery, CDC/NCIRD
- **Phase III Randomized Observer-Blind Comparator-Controlled study of Afluria Quadrivalent for Children 6 through 59 months**
 - Dr. Gregg Sylvester, Seqirus
- **Case-Control Study of Inactivated Influenza Vaccine and Spontaneous Abortion in the Vaccine Safety Datalink, 2012-13, 2013-14, and 2014-15**
 - Dr. Jim Donahue, Marshfield Clinic Research Institute
- **Summary and Work Group Considerations**
 - Dr. Lisa Grohskopf, CDC/NCIRD